Why Is Altimmune (ALT) Stock Up 14% Today?

Altimmune (NASDAQ:ALT) stock is rising higher on Monday but it’s not actually due to any news from the clinical-stage biopharmaceutical company.Instead, a clinical trial update from rival Zealand Pharma is behind the increase in ALT stock today. That comes after the company provided results from a Phase 2 clinical trial of liver disease treatment and weight loss drug survodutide.The big news here is that the 6mg dose of the drug was found to be safe during the MASH liver disease clinical trial. That’s a hig ...